June 10, 2021 12:23 PM EDT

Novartis cuts jobs at Swiss plant as a UK facility sits in a holding pattern with 200 positions on the line — reports

Kyle Blankenship

Swiss drugmaker Novartis launched an ambitious workforce restructuring plan back in 2018 with plans to cut more than 2,000 jobs across the supply chain …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis cuts jobs at Swiss plant as a UK facility sits in a holding pattern with 200 positions on the line — reports

Kyle Blankenship

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus

No­var­tis cuts jobs at Swiss plant as a UK fa­cil­i­ty sits in a hold­ing pat­tern with 200 po­si­tions on the line — re­ports

Kyle Blankenship

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Novartis cuts jobs at Swiss plant as a UK facility sits in a holding pattern with 200 positions on the line — reports

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus